Literature DB >> 35610050

Macrophage Migration Inhibitory Factor (MIF) Makes Complex Contributions to Pain-Related Hyperactivity of Nociceptors after Spinal Cord Injury.

Alexis G Bavencoffe1, Emily A Spence2, Michael Y Zhu2, Anibal Garza-Carbajal2, Kerry E Chu2, Ona E Bloom3, Carmen W Dessauer2, Edgar T Walters2.   

Abstract

Neuropathic pain is a major, inadequately treated challenge for people with spinal cord injury (SCI). While SCI pain mechanisms are often assumed to be in the central nervous system, rodent studies have revealed mechanistic contributions from primary nociceptors. These neurons become chronically hyperexcitable after SCI, generating ongoing electrical activity (OA) that promotes ongoing pain. A major question is whether extrinsic chemical signals help to drive OA after SCI. People living with SCI exhibit acute and chronic elevation of circulating levels of macrophage migration inhibitory factor (MIF), a cytokine implicated in preclinical pain models. Probable nociceptors isolated from male rats and exposed to a MIF concentration reported in human plasma (1 ng/ml) showed hyperactivity similar to that induced by SCI, although, surprisingly, a ten-fold higher concentration failed to increase excitability. Conditioned behavioral aversion to a chamber associated with peripheral MIF injection suggested that MIF stimulates affective pain. A MIF inhibitor, Iso-1, reversed SCI-induced hyperexcitability. Unlike after SCI, acute MIF-induced hyperexcitability was only partially abrogated by inhibiting ERK signaling. Unexpectedly, MIF concentrations that induced hyperactivity in nociceptors from Naïve animals, after SCI induced a long-lasting conversion from a highly excitable nonaccommodating type to a rapidly accommodating, hypoexcitable type, possibly as a homeostatic response to prolonged depolarization. Treatment with conditioned medium from cultures of dorsal root ganglion (DRG) cells obtained after SCI was sufficient to induce MIF-dependent hyperactivity in neurons from Naïve rats. Thus, changes in systemic and DRG levels of MIF may help to maintain SCI-induced nociceptor hyperactivity that persistently promotes pain.Significance Statement:Chronic neuropathic pain is a major challenge for people with spinal cord injury (SCI). Pain can drastically impair quality of life, and produces substantial economic and social burdens. Available treatments, including opioids, remain inadequate. This study shows that the cytokine macrophage migration inhibitory factor (MIF) can induce pain-like behavior and plays an important role in driving persistent ongoing electrical activity in injury-detecting sensory neurons (nociceptors) in a rat SCI model. The results indicate that SCI produces an increase in MIF release within sensory ganglia. Low MIF levels potently excite nociceptors, but higher levels trigger a long-lasting hypoexcitable state. These findings suggest that therapeutic targeting of MIF in neuropathic pain states may reduce pain and sensory dysfunction by curbing nociceptor hyperactivity.
Copyright © 2022 the authors.

Entities:  

Year:  2022        PMID: 35610050      PMCID: PMC9270921          DOI: 10.1523/JNEUROSCI.1133-21.2022

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.709


  66 in total

1.  Cisplatin-induced activation and functional modulation of satellite glial cells lead to cytokine-mediated modulation of sensory neuron excitability.

Authors:  Markus Leo; Linda-Isabell Schmitt; Andrea Kutritz; Christoph Kleinschnitz; Tim Hagenacker
Journal:  Exp Neurol       Date:  2021-03-14       Impact factor: 5.330

Review 2.  Opioids should not be prescribed for chronic pain after spinal cord injury.

Authors:  Thomas N Bryce
Journal:  Spinal Cord Ser Cases       Date:  2018-07-27

3.  Activation of KCNQ Channels Suppresses Spontaneous Activity in Dorsal Root Ganglion Neurons and Reduces Chronic Pain after Spinal Cord Injury.

Authors:  Zizhen Wu; Lin Li; Fuhua Xie; Junhui Du; Yan Zuo; Jeffrey A Frost; Susan M Carlton; Edgar T Walters; Qing Yang
Journal:  J Neurotrauma       Date:  2017-02-27       Impact factor: 5.269

4.  A Transcriptomic Analysis of Neuropathic Pain in Rat Dorsal Root Ganglia Following Peripheral Nerve Injury.

Authors:  Wuping Sun; Dongquan Kou; Zhijian Yu; Shaomin Yang; Changyu Jiang; Donglin Xiong; Lizu Xiao; Qiwen Deng; Hengtao Xie; Yue Hao
Journal:  Neuromolecular Med       Date:  2019-12-19       Impact factor: 3.843

5.  Enhancement of macrophage migration inhibitory factor (MIF) expression in injured epidermis and cultured fibroblasts.

Authors:  R Abe; T Shimizu; A Ohkawara; J Nishihira
Journal:  Biochim Biophys Acta       Date:  2000-01-03

Review 6.  Neuropathic Pain and Spinal Cord Injury: Phenotypes and Pharmacological Management.

Authors:  Eva Widerström-Noga
Journal:  Drugs       Date:  2017-06       Impact factor: 9.546

7.  The persistence of a long-term negative affective state following the induction of either acute or chronic pain.

Authors:  Michele Hummel; Peimin Lu; Terri A Cummons; Garth T Whiteside
Journal:  Pain       Date:  2008-10-21       Impact factor: 6.961

Review 8.  MIF in autoimmunity and novel therapeutic approaches.

Authors:  Stanislava Stosic-Grujicic; Ivana Stojanovic; Ferdinando Nicoletti
Journal:  Autoimmun Rev       Date:  2008-08-20       Impact factor: 9.754

9.  Macrophage migration inhibitory factor mediates peripheral nerve injury-induced hypersensitivity by curbing dopaminergic descending inhibition.

Authors:  Xian Wang; Shaolei Ma; Haibo Wu; Xiaofeng Shen; Shiqin Xu; Xirong Guo; Maria L Bolick; Shizheng Wu; Fuzhou Wang
Journal:  Exp Mol Med       Date:  2018-02-16       Impact factor: 8.718

10.  Sensitization of knee-innervating sensory neurons by tumor necrosis factor-α-activated fibroblast-like synoviocytes: an in vitro, coculture model of inflammatory pain.

Authors:  Sampurna Chakrabarti; Zoe Hore; Luke A Pattison; Sylvine Lalnunhlimi; Charity N Bhebhe; Gerard Callejo; David C Bulmer; Leonie S Taams; Franziska Denk; Ewan St John Smith
Journal:  Pain       Date:  2020-09-01       Impact factor: 6.961

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.